Third‐line antiretroviral therapy, including raltegravir (RAL), darunavir (DRV/r) and/or etravirine (ETR), is well tolerated and achieves durable virologic suppression over 144 weeks in resource‐limited settings: ACTG A5288 strategy trial
Anchalee Avihingsanon(Chulalongkorn University), Marije Van Schalkwyk, Aggrey Bukuru(Joint Clinical Research Centre), Breno Santos(Hospital Nossa Senhora da Conceição), Beatriz Grinsztejn(Fundação Oswaldo Cruz), Catherine Godfrey(United States Department of State), Esmelda Montalbán, Robert A. Salata(Case Western Reserve University), Beatrice Wangari Ndege(Moi University), John W. Mellors(Textron Systems (United Kingdom)), Wadzanai Samaneka(University of Zimbabwe), Cornelius Munyanga(Kamuzu Central Hospital), Javier Valencia(Asociación Civil Impacta Salud y Educación), Evelyn Hogg(Social and Scientific Systems (United States)), Peter Mugyenyi(Joint Clinical Research Centre), Maganizo Chagomerana(University of North Carolina at Chapel Hill), Patcharaphan Sugandhavesa(Chiang Mai University), Vidya Mave(Johns Hopkins University), Sharlaa Badal‐aesen(Helen Joseph Hospital), N Kumarasamy(YR Gaitonde Centre for AIDS Research and Education), Sandra Wagner Cardoso(Instituto Evandro Chagas), Lerato Mohapi, Robert Gross(University of Cape Town), Caitlyn McCarthy(Cancer Research And Biostatistics), Carole L. Wallis, Rosie Mngqibisa, Sandy Nerette Fontain(Gheskio Centers), Cecilia Kanyama, Michael D. Hughes(Virginia Tech), Ann C. Collier(University of Washington), Rode Secours(Gheskio Centers), Robert T. Schooley(Unknown)
Cited by 13
Related Papers
Prevention of HIV-1 Infection with Early Antiretroviral Therapy
|New England Journal of Medicine|2011|7k
The Efficacy of Azidothymidine (AZT) in the Treatment of Patients with AIDS and AIDS-Related Complex
|New England Journal of Medicine|1987|3k
Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19
|New England Journal of Medicine|2021|2.6k
Treatment with Indinavir, Zidovudine, and Lamivudine in Adults with Human Immunodeficiency Virus Infection and Prior Antiretroviral Therapy
|New England Journal of Medicine|1997|1.9k
Antiretroviral Therapy for the Prevention of HIV-1 Transmission
|New England Journal of Medicine|2016|1.7k